Authored article By Urvi Lakhwani, Chief Nutritionist at DeAge
Ask most people who live longer, men or women, and they’ll get it right. Women outlive men in nearly every country on record, by an average of four to six years. A pattern so consistent across human history and so many other mammal species that biologists call it one of the most robust features of biology, full stop.
But ask a different question: who spends more years unwell? and the answer flips. Women live longer and get sicker doing it. It is the male-female health-survival paradox. Women survive; men suffer less along the way.²
That distinction matters more than the survival statistic itself. A longevity strategy built only on “add years” misses the actual problem. The real objective is narrowing the gap between lifespan and healthspan, and doing that requires understanding why the gap exists in the first place.
Why women live longer
A few mechanisms are at play here.
The first is Genetic. Females carry two X chromosomes, and in mammals one is largely inactivated in each cell. Some genes escape this silencing, meaning they remain expressed from both X chromosomes and at higher levels in females. This X-linked biology may contribute to differences in aging and longevity, while also helping explain women’s stronger immune responses and greater susceptibility to autoimmune disease. What looks like an advantage in one context can become a liability in another.
The second is hormonal. Estrogen has systemic protective effects: on blood vessels, on bone, on metabolic regulation, that operate for as long as the ovaries are producing it. Which means female longevity biology isn’t a fixed trait so much as a time-limited one. It’s strongly tied to a specific biological window, and that window closes at menopause. Everything in the next two sections follows from that fact.
Where the risk actually concentrates
Bone. Nearly half of women over 50 will experience an osteoporotic fracture in their lifetime, and postmenopausal bone loss accelerates faster than most people expect. The stakes aren’t cosmetic: hip fractures in older women carry up to a 30% mortality rate within one year. Sarcopenia, i.e., age-related muscle loss, compounds the problem, since women start with less muscle mass than men and lose it faster once estrogen drops. Bone and muscle loss aren’t separate issues here; they’re mechanistically linked, and both accelerate on the same hormonal timeline.
Cardiovascular risk. This one is about timing, not just hormones. Women who experience earlier menopause show a higher risk of cardiovascular events before age 60, but that elevated risk fades by 70. Estrogen appears to be cardioprotective specifically while it’s present and while the vascular system is still relatively healthy; once both change, the relationship changes too.
Ovarian aging. Menopause isn’t merely the end of the reproductive or fertile window in a woman’s life, it’s the near-total loss of a hormone that the rest of the body has depended on for systemic protection. Treating menopause purely as a reproductive event misses what’s actually happening: a coordinated withdrawal of protection across bone, cardiovascular, and metabolic systems, all on roughly the same timeline.
The research gap itself is a risk factor. Much of the pharmacology underlying “longevity science” including the interventions, the compounds, the protocols, was developed and tested predominantly in male animal models. In the geroprotective compounds that have been tested in both sexes, real sexual dimorphism in response shows up often enough that assuming a male-validated intervention will behave identically in female physiology is itself a risk, not a neutral assumption. This is less a gap in nature and more a gap in how science got built and it’s the one place where formulation and protocol design can actually do something about the imbalance.
What this means in practice
This is where the biology above should change decisions, not just inform them.
Resistance training is not optional, and the timing matters more than most people realize. The evidence on this is now specific enough to act on. High-intensity resistance and impact training (HiRIT) — loaded resistance work combined with impact-based movement — has shown measurable gains in lumbar spine bone density in postmenopausal women with low bone mass, in trials designed specifically to test this.⁹ Frequency matters too: interventions delivered at least three times a week consistently outperform less frequent training across lumbar spine, femoral neck, and total hip bone density measures.¹⁰
But the more important detail is when to start. Bone responds to loading, but the remodeling cycle itself takes three to eight months, and most studies show it takes at least six to nine months of consistent training before density gains show up on a scan. That means starting resistance training reactively, after a fracture or a diagnosis, is starting from behind. Feasibility trials are now specifically testing high-intensity protocols in perimenopausal and early postmenopausal women before the accelerated bone-loss phase is fully underway, precisely because earlier intervention while the system is still relatively responsive appears to matter. The takeaway for anyone in their late 30s to mid-40s: this is not a “wait until symptoms show up” intervention.
Hormone therapy is a timing question, not a yes/no question. For two decades, the Women’s Health Initiative made hormone replacement therapy sound like a categorical cardiovascular risk. That conclusion doesn’t hold up under closer inspection. The original WHI trial enrolled women with an average age of 63, more than a decade past typical menopause onset. When the data was later stratified by age and time-since-menopause, a different pattern emerged: what’s now called the “timing hypothesis.” Hormone therapy initiated within about 10 years of menopause onset, or before age 60, is associated with favorable cardiovascular outcomes; initiated later, in women whose arteries have already begun accumulating unstable plaque, the same therapy is associated with worse outcomes. Randomized trials specifically designed to test this, comparing therapy started under 6 years post-menopause versus over 10 years post-menopause, found reduced progression of arterial thickening in the early-start group and no benefit in the late-start group. The mechanism lines up with what you’d expect: estrogen supports vascular function well when introduced to a still-healthy endothelium, and does the opposite once the vasculature has already changed.
Generic protocols deserve more scrutiny, not less. Given how much of the underlying research was validated primarily in male models, any intervention, dosing, fasting windows, supplement timing, that hasn’t been separately evaluated in female physiology should be treated as an open question rather than a settled one. This isn’t a reason to avoid intervention. It’s a reason to formulate and dose with the hormonal cycle and menopausal status actually in view, rather than applying a male-calibrated default and assuming it translates.
Women aren’t disadvantaged or advantaged in longevity, they’re ahead on one metric and behind on another, and those two metrics have different underlying biology. Closing the healthspan gap doesn’t mean waiting for lifespan to catch down. It means acting on the specific, well-documented mechanisms, bone remodeling timelines, the hormonal cardiovascular window, a research base still catching up to female physiology, early enough that they still respond.
